Circ-SUZ12 Protects Cardiomyocytes from Hypoxia-Induced Dysfunction Through Upregulating SUZ12 Expression to Activate Wnt/ß-catenin Signaling Pathway.

Acute myocardial infarction (AMI) is a common coronary artery disease. This study attempted to reveal the impact of circ-SUZ12 (hsa_circ_0042961) on cardiomyocyte injury after exposure to hypoxia.Circ-SUZ12 was screened out from the GEO dataset GSE169594. RNA expression and protein level were detected by quantitative real-time PCR (qRT-PCR) and Western blot, respectively. The characteristics of circ-SUZ12 were identified by measuring its resistance to Rnase R or actinomycin D (Act D) treatment. CCK-8 and EdU assays were performed to explore the viability of AC16 cells. Cell apoptosis was assessed through TUNEL assay and flow cytometry analysis. Mechanism experiments were performed to investigate the downstream molecular mechanism of circ-SUZ12.Circ-SUZ12 was highly expressed in blood samples of AMI patients in the GEO dataset and lowly expressed in hypoxia-treated cardiomyocytes. Overexpression of circ-SUZ12 reversed hypoxia-induced cardiomyocyte injury. Circ-SUZ12 regulated SUZ12 polycomb repressive complex 2 subunit (SUZ12) expression by recruiting FUS protein. SUZ12 activated the Wnt/ß-catenin signaling pathway by increasing the H3K27me3 level in microRNA (miR)-526b-5p promoter to release catenin beta 1 (CTNNB1). CTNNB1 depletion reversed the effect of circ-SUZ12 on the viability and apoptosis of hypoxia-induced cardiomyocytes.Circ-SUZ12 protects cardiomyocytes from hypoxia-induced dysfunction through upregulating SUZ12 expression to activate the Wnt/ß-catenin signaling pathway.